Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 10/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL13736056 | 0.89 | PLAU (0.35) | PLAUF2PLATELANEBTN3A1 | |
| SCHEMBL13736066 | 0.83 | PLAU (0.37) | PLAUF2PLATMAOBELANE | |
| SCHEMBL2243204 | 0.80 | F2 (0.43) | PLAUF2PLATELANEBTN3A1 | |
| Trifluoroacetic Acid SCHEMBL13736165 | 0.79 | PLAU (0.32) | PLAUF2PLAT | |
| SCHEMBL2249449 | 0.78 | PLAU (0.53) | PLAUF2PLATELANEPLG | |
| Trifluoroacetic Acid SCHEMBL13736749 | 0.77 | PLAU (0.64) | PLAUF2PLATPLG | |
| SCHEMBL13736751 | 0.77 | PLAU (0.41) | PLAUF2PLATPLG | |
| SCHEMBL2245473 | 0.76 | PLAU (0.42) | PLAUF2PLATELANEBTN3A1 | |
| Trifluoroacetic Acid SCHEMBL13738338 | 0.76 | PLAU (0.32) | PLAUF2PLAT | |
| Trifluoroacetic Acid SCHEMBL13736328 | 0.69 | PLAU (0.53) | PLAUF2PLATPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| EP-2707034-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | Universiteit Antwerpen (BE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | PLAU 1/4885F2 165/4885PLAT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.